Article · 13 Feb 2026
Conference abstractPublished 23 Nov 2012
Saudi pharmaceutical market: Current, future and RandD
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The Saudi pharmaceutical market is the largest in the GCC region. The vast majority of the market is comprised of imports. Many foreign companies have been entering the Kingdom of the Saudi Arabia drug market because of its pricing structure and rapid approval processes. Additionally, private and public are operate under no tax policies. The government supports the regulation and the drug traffic through (SFDA), which was established by Saudi Authorities in 2003. The SFDA intended to provide high quality medicine for the fast growing population. As of 2012 Saudi drug market size is expected to improve its annual growth of 4.74%, which estimated to reach SAR13.1 billion ($3.49 billion) by the end of this year. Local manufactures supplied only 16% of the total pharmaceutical market. Imported pharmaceuticals which occupy the 84%, from foreign countries are estimated to grow by 5.25% and projected to reach $2.88 billion this year. There are currently about 5,700 registered drugs sold through more than 4,500 pharmacies through the country. Saudi government is planning to improve the local pharmaceutical industry through R&D. Cultural revolution and utilization of high technologies are the first necessary steps for Saudi pharma to build the R&D engine. The plan includes joining the intellectual efforts with technology transferee professionals and building an effective postgraduate program with postdoctoral training. The country plan also involves establishing ?university-industrygovernment triumvirate? as a normative innovation network.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Naser L. Rezk”

